Total Q3 2025 sales reached £8.5 billion, up 7% AER and 8% CER123
Specialty Medicines sales £3.4 billion (+16%), with Oncology +39%, HIV +12%, and Respiratory, Immunology & Inflammation +15%1234
Vaccines sales £2.7 billion (+2%), driven by Shingrix (+13%) and Arexvy (+36%]1234
General Medicines sales £2.5 billion (+4%), led by Trelegy (+25%]1234
Core operating profit +11%, Core EPS +14%123
2025 guidance upgraded:
Sales growth 6-7% (from 3-5%), Core OP growth 9-11% (from 6-8%), Core EPS growth 10-12% (from 6-8%) at CER23
Sources:
1. https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf
2. https://www.jamessharp.co.uk/market-news/gsk-publish-3rd-quarter-results/
3. https://www.gsk.com/media/0qfjbtd3/q3-2025-results-slides.pdf